Pharmaceutical Statistics has just published a special issue in honour of Andy Grieve to celebrate his 70th birthday, guest edited by Stephen Senn and Mike K. Smith, with a foreword by Sir Adrian Smith.
The authors of the assembled papers have either collaborated with Andy as a colleague or co-author or have been influenced by his work. Their varied and interesting contributions, which, as is fitting in view of the scope of Andy’s work, cover professional, practical, and methodological aspects of biostatistics as applied to the pharmaceutical industry.
The articles in the issue are:
. Reflecting on Andy Grieve’s influence and innovation: A personal perspective. Pharmaceutical Statistics. 2022; 21( 4): 702–705. doi:10.1002/pst.2220
, . Do statisticians count? A prior and posterior viewpoint. Pharmaceutical Statistics. 2022; 21( 4): 706–711. doi:10.1002/pst.2229
, . From innovative thinking to pharmaceutical industry implementation: Some success stories. Pharmaceutical Statistics. 2022; 21( 4): 712–719. doi:10.1002/pst.2222
, . The Acute Stroke Therapy by Inhibition of Neutrophils study – Key features and impact. Pharmaceutical Statistics. 2022; 21( 4): 720–728. doi:10.1002/pst.2218
, , . Simulation-based sequential design. Pharmaceutical Statistics. 2022; 21( 4): 729–739. doi:10.1002/pst.2216
, . Informed decision-making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments. Pharmaceutical Statistics. 2022; 21( 4): 740–756. doi:10.1002/pst.2219. OPEN ACCESS
, , . Rationale for the update algorithm of the graphical approach to sequentially rejective multiple test procedures. Pharmaceutical Statistics. 2022; 21( 4): 757–763. doi:10.1002/pst.2227
. Study-design in pandemics: From surveillance and performance-evaluation to licensing and pharmacovigilance. Pharmaceutical Statistics. 2022; 21( 4): 764–777. doi:10.1002/pst.2217 OPEN ACCESS
. The cross-over of statistical thinking and practices: A pandemic catalyst. Pharmaceutical Statistics. 2022; 21( 4): 778–789. doi:10.1002/pst.2221 FREE ACCESS
. The design and analysis of vaccine trials for COVID-19 for the purpose of estimating efficacy. Pharmaceutical Statistics. 2022; 21( 4): 790–807. doi:10.1002/pst.2226 OPEN ACCESS
. Viewpoint: Do not resurrect the two-stage procedure. Pharmaceutical Statistics. 2022; 21( 4): 808–814. doi:10.1002/pst.2224